赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNY 赛诺菲安万特

盘后交易 05-12 17:21:41 EDT

51.06

+1.16

+2.32%

盘后51.06

+0.000.00%

16:39 EDT

最高51.22	最低49.88	成交量279.71万
今开49.97	昨收49.90	日振幅2.69%
总市值1,244亿	流通市值1,120亿	总股本24.36亿
成交额1.42亿	换手率0.13%	流通股本21.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":51.06,"timestamp":1747080000000,"preClose":49.9,"halted":0,"volume":2797148,"hourTrading":{"tag":"盘后","latestPrice":51.06,"preClose":51.06,"latestTime":"16:39 EDT","volume":30225,"amount":1543267.3425,"timestamp":1747082351293},"delay":0,"floatShares":2193984969,"shares":2436106420,"eps":2.726027,"marketStatus":"盘后交易","change":1.16,"latestTime":"05-12 17:21:41 EDT","open":49.97,"high":51.22,"low":49.88,"amount":141512315.831312,"amplitude":0.026854,"askPrice":52.15,"askSize":4,"bidPrice":50.59,"bidSize":1,"shortable":3,"etf":0,"ttmEps":2.726027,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1747094400000},"marketStatusCode":4,"adr":1,"adrRate":0.5,"listingDate":1025496000000,"exchange":"NASDAQ","adjPreClose":49.9,"dividendRate":0.043322,"preHourTrading":{"tag":"盘前","latestPrice":49.96,"preClose":49.9,"latestTime":"09:29 EDT","volume":38869,"amount":1920184.4158839998,"timestamp":1747056587094},"postHourTrading":{"tag":"盘后","latestPrice":51.06,"preClose":51.06,"latestTime":"16:39 EDT","volume":30225,"amount":1543267.3425,"timestamp":1747082351293},"volumeRatio":1.226719,"impliedVol":0.3315,"impliedVolPercentile":0.84},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"2534190190","title":"赛诺菲(SNY.US)1款抗体新药报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2534190190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534190190?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:12","pubTimestamp":1746753155,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月8日，CDE官网显示，赛诺菲的“注射用卡普赛珠单抗”报上市，适应症为与血浆置换和免疫抑制疗法联合治疗获得性血栓性血小板减少性紫癜，适用群体范围为成人和12岁及以上体重至少40kg的青少年患者。aTTP是一种罕见的、危及生命的自身免疫性血液疾病。卡普赛珠单抗是一种针对vWF的纳米抗体，旨在抑制vWF和血小板之间的相互作用。该药最初由Ablynx开发，赛诺菲于2018年收购了Ablynx公司，从而将其收入麾下。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛诺菲(SNY.US)1款抗体新药报上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","BK4585","BK4007","BK4588","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2532825331","title":"赛诺菲安万特盘中异动 早盘大幅上涨3.01%报55.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532825331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532825331?lang=zh_cn&edition=full","pubTime":"2025-05-02 22:55","pubTimestamp":1746197741,"startTime":"0","endTime":"0","summary":"北京时间2025年05月02日22时55分，赛诺菲安万特股票出现异动，股价急速上涨3.01%。截至发稿，该股报55.73美元/股，成交量56.947万股，换手率0.02%，振幅0.78%。赛诺菲安万特股票所在的制药行业中，整体涨幅为1.82%。赛诺菲安万特公司简介：赛诺菲开发和销售的药物主要集中在肿瘤学、免疫学、心血管疾病、糖尿病、非处方治疗和疫苗领域。总收入的 40% 多一点来自美国，25% 来自欧洲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502225541974d70da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502225541974d70da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BFXG1179.USD","SNY","BK4588","BK4585"],"gpt_icon":0},{"id":"2529981952","title":"重磅药物Dupixent驱动增长 赛诺菲一季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2529981952","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529981952?lang=zh_cn&edition=full","pubTime":"2025-04-24 15:45","pubTimestamp":1745480707,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲第一季度利润超预期，其重磅皮肤科和哮喘药物Dupixent的强劲需求功不可没。财报显示，赛诺菲一季度营收为 98.9 亿欧元，同比下降 5.4%，超出预期 1.2 亿欧元；经项目调整后的每股收益为1.79欧元，高于分析师预估的1.67欧元。赛诺菲当季99亿欧元销售额中有近半数来自美国市场，凸显其对全球最大医药市场的依赖。得益于Dupixent销售额增长20%至35亿欧元，公司季度总营收超出市场预估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424194955974387ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424194955974387ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BFXG1179.USD","BK4007","SNY","BK4588"],"gpt_icon":0},{"id":"2528303976","title":"18.45亿美元！赛诺菲(SNY.US)重金加码自免和炎症性肠病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2528303976","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528303976?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:44","pubTimestamp":1744962285,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，当地时间4月17日，Earendil Labs宣布与赛诺菲就两种潜在的首创双特异性抗体达成许可协议，用于自身免疫性和炎症性肠病领域。根据协议，赛诺菲将获得两种双特异性抗体 HXN-1002 和 HXN-1003 的全球独家授权，这两种抗体均将利用 Earendil Labs 专有的人工智能和高通量发现与研究平台进行开发。作为协议的一部分，Earendil Labs将获得1.25亿美元的预付款，并有资格获得总计高达17.2亿美元的开发和商业里程碑付款，其中包括 5000 万美元的近期付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"18.45亿美元！赛诺菲(SNY.US)重金加码自免和炎症性肠病领域","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","BK4585","IE00BFXG1179.USD","BK4007","BK4588"],"gpt_icon":0},{"id":"2527841914","title":"金十数据整理：每日美股市场要闻速递（4月15日，周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2527841914","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527841914?lang=zh_cn&edition=full","pubTime":"2025-04-15 21:01","pubTimestamp":1744722113,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["0O59.UK","BA","159934","GDX","LU1267930490.SGD","SNY","LU0708994859.HKD","GFS","BK4573","LU0823414478.USD","LU2237443622.USD","AMD","IE00BJLML261.HKD","BK4108","IE00BKVL7J92.USD","TWmain","EWT","03145","GCmain","IAU","LU0096364046.USD","NFLX","LU2106854487.HKD","518880","159831","LU1988902786.USD","LU0724617625.USD","SG9999014898.SGD","LU1935042215.USD","TSM","MGCmain","DUST","SGXZ81514606.USD","GOOGL","LU1201861249.SGD","159813","GLD","LU0077335932.USD","LU1066051225.USD","BK4579","BK4187","SGCmain","BAC","SGUmain","BK4514","LU1242518857.USD","GOOG","NUGT","USJW.SI"],"gpt_icon":1},{"id":"2527662894","title":"Dupixent专利到期后恐陷“青黄不接” 赛诺菲(SNY.US)下一代哮喘药临床试验结果不佳","url":"https://stock-news.laohu8.com/highlight/detail?id=2527662894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527662894?lang=zh_cn&edition=full","pubTime":"2025-04-15 17:09","pubTimestamp":1744708183,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲研发的下一代实验性哮喘药物阿米特利单抗在针对中重度哮喘患者的试验中，未能显著减少病情发作次数，将该药物的前景蒙上阴影，难以承担起弥补赛诺菲重磅药物度普利尤单抗专利到期所造成损失的重任。周二早盘，赛诺菲股价下跌1.1%。尽管如此，由于在特定的患者亚组中，该药物展现出了在肺功能、哮喘控制方面有临床意义的改善，且能显著减少病情发作，赛诺菲仍计划在后期临床试验中继续对其进行测试。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","SNY","BK4007","BK1576","IE00BFXG1179.USD","BK1583","BK4585","BK4588"],"gpt_icon":0},{"id":"2526875613","title":"赛诺菲安万特盘中异动 快速上涨3.00%报51.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2526875613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2526875613?lang=zh_cn&edition=full","pubTime":"2025-04-12 00:36","pubTimestamp":1744389381,"startTime":"0","endTime":"0","summary":"北京时间2025年04月12日00时36分，赛诺菲安万特股票出现异动，股价大幅拉升3.00%。截至发稿，该股报51.15美元/股，成交量130.076万股，换手率0.05%，振幅1.87%。赛诺菲安万特股票所在的制药行业中，整体涨幅为1.16%。赛诺菲安万特公司简介：赛诺菲开发和销售的药物主要集中在肿瘤学、免疫学、心血管疾病、糖尿病、非处方治疗和疫苗领域。总收入的 40% 多一点来自美国，25% 来自欧洲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250412003621a6b7fb58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250412003621a6b7fb58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BFXG1179.USD","BK4588","BK4007","SNY"],"gpt_icon":0},{"id":"2518464787","title":"再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2518464787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518464787?lang=zh_cn&edition=full","pubTime":"2025-03-11 07:38","pubTimestamp":1741649927,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日前，再生元和赛诺菲在2025年美国皮肤科学会年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent在治疗中重度大疱性类天疱疮成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请已经获得FDA授予的优先审评资格，有望在今年年中获批。全球有超过100万名患者正在接受Dupixent治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","SNY","LU1917777945.USD","LU2468319806.SGD","LU0053666078.USD","LU2106854487.HKD","LU2023250504.SGD","LU0889565916.HKD","LU0823416689.USD","LU0114720955.EUR","REGN","BK4139","LU2362541273.HKD","LU2362541513.USD","LU2089984988.USD","LU0882574055.USD","BK4585","LU0109394709.USD","LU0289739699.SGD","BK4007","LU1974910355.USD","BK4588","LU2237438978.USD","LU2362540622.SGD","IE00BFXG1179.USD","LU0320765992.SGD"],"gpt_icon":1},{"id":"2516315632","title":"赛诺菲安万特盘中异动 早盘股价大涨3.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516315632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516315632?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012349,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，赛诺菲安万特股票出现波动，股价急速上涨3.41%。截至发稿，该股报56.33美元/股，成交量49.8292万股，换手率0.02%，振幅0.15%。机构评级方面，在所有24家参与评级的机构中，83%的券商给予买入建议，13%的券商给予持有建议，4%的券商给予卖出建议。赛诺菲安万特股票所在的制药行业中，整体跌幅为0.25%。赛诺菲安万特公司简介：赛诺菲开发和销售的药物主要集中在肿瘤学、免疫学、心血管疾病、糖尿病、非处方治疗和疫苗领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223229a25d4007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223229a25d4007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","SNY","BK4007","IE00BFXG1179.USD","BK4588"],"gpt_icon":0},{"id":"2514099391","title":"金十数据整理：每日美股市场要闻速递（2月25日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099391","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514099391?lang=zh_cn&edition=full","pubTime":"2025-02-25 21:08","pubTimestamp":1740488922,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NBIS","NVDU","2NVD.UK","LU0203201768.USD","NVDD","SNVD.UK","TEVA","ZM","161631","3NVD.UK","03165","LU2361044865.SGD","SNY","NVD3.UK","BK4505","LU0265550359.USD","SEC.AU","YY","LU0820561909.HKD","0O59.UK","BK4513","NVD","LU1720051017.SGD","INTC","NVDS.UK","NVDS","ASML","NVD2.UK","NVDX","TSYW.SI","API","03347","HK0000306701.USD","NVIW.SI","IE0004086264.USD","LU2065171402.SGD","TSLL","BK4099","SG9999002232.USD","BIDU","NVDY","HD","159813","TSLA","RBLX","NVDL","AI","LU0225283273.USD","NVDA"],"gpt_icon":1},{"id":"2514203216","title":"赛诺菲(SNY.US)抗过敏药“非索非那定”新适应症在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2514203216","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514203216?lang=zh_cn&edition=full","pubTime":"2025-02-25 13:50","pubTimestamp":1740462640,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月25日，中国国家药监局药品审评中心官网最新公示，赛诺菲申报的盐酸非索非那定口服混悬液新适应症上市申请获得受理。此前非索非那定片已经在中国获批，用于治疗过敏性鼻炎及慢性特发性荨麻疹。根据赛诺菲公开资料介绍，非索非那定是二代新型抗组胺药，兼具拮抗组胺和抗炎作用，具有起效快、24小时长效，且不引起嗜睡，脑部受体占有率低等特点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","IE00BFXG1179.USD","BK4585","BK4588","BK4007"],"gpt_icon":1},{"id":"2512152093","title":"赛诺菲(SNY.US)和再生元(REGN.US)的度普利尤单抗获FDA优先审查 或成为美国首款治疗BP的靶向药","url":"https://stock-news.laohu8.com/highlight/detail?id=2512152093","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512152093?lang=zh_cn&edition=full","pubTime":"2025-02-18 21:15","pubTimestamp":1739884509,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月18日，赛诺菲和再生元共同宣布FDA已受理度普利尤单抗用于治疗成人大疱性类天疱疮  的补充生物制品许可申请  的优先审查，PDUFA日期为2025年6月20日。如果获得批准，度普利尤单抗将成为美国第一个也是唯一一个治疗BP的靶向药物。BP是一种慢性、衰弱和复发性皮肤病，具有潜在的2型炎症，通常发生在老年人群中。2024年9月，度普利尤单抗治疗BP的II/III期ADEPT研究传来捷报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LU0162691827.USD","LU0109394709.USD","REGN","LU0053666078.USD","LU0114720955.EUR","LU2362540622.SGD","LU0058720904.USD","BK4585","LU0889565916.HKD","LU0882574055.USD","LU2468319806.SGD","LU0823416689.USD","IE00BFXG1179.USD","BK4201","LU1162221912.USD","LU1974910355.USD","LU2237438978.USD","LU0072461881.USD","LU2023250504.SGD","LU0320765646.SGD","LU0289739699.SGD","BK4007","LU1917777945.USD","BK4588","LU0320765992.SGD","LU2106854487.HKD","LU1829250122.USD","LU2089984988.USD","SNY","LU2362541273.HKD","LU2362541513.USD","BP"],"gpt_icon":0},{"id":"2511651651","title":"赛诺菲(SNY.US)终止一项大肠杆菌疫苗试验 损失约2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511651651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511651651?lang=zh_cn&edition=full","pubTime":"2025-02-13 16:56","pubTimestamp":1739437004,"startTime":"0","endTime":"0","summary":"赛诺菲在一份声明中表示，由于这一最新的决定，公司在2024年第四季度的财报中记录了大约2.5亿美元的减值损失。但是赛诺菲表示这一决定不会对赛诺菲当前财年的财务预期产生任何影响。赛诺菲与强生公司表示，在一项独立的数据监测委员会评估后，决定终止这项重要的临床后期研究。目前，针对大肠杆菌败血症尚无特定的预防疫苗。赛诺菲已经支付了2.5亿美元作为协议的一部分，并原计划在未来根据商业里程碑进行进一步的支付款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1249403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","BK4588","BK4007","SNY","159646","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":-0.0999},{"period":"1month","weight":-0.0256},{"period":"3month","weight":-0.0647},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0249},{"period":"ytd","weight":0.0346}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0606},{"period":"6month","weight":-0.0566},{"period":"1year","weight":0.0849},{"period":"ytd","weight":-0.0371}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.521739,"avgChangeRate":-0.016351},{"month":2,"riseRate":0.304348,"avgChangeRate":-0.020169},{"month":3,"riseRate":0.826087,"avgChangeRate":0.032485},{"month":4,"riseRate":0.652174,"avgChangeRate":0.024644},{"month":5,"riseRate":0.521739,"avgChangeRate":-0.004433},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.014468},{"month":7,"riseRate":0.5,"avgChangeRate":0.018684},{"month":8,"riseRate":0.478261,"avgChangeRate":-0.011185},{"month":9,"riseRate":0.565217,"avgChangeRate":0.010124},{"month":10,"riseRate":0.521739,"avgChangeRate":-0.00342},{"month":11,"riseRate":0.608696,"avgChangeRate":-0.001805},{"month":12,"riseRate":0.695652,"avgChangeRate":0.031696}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}